Breaks Categories: News

MondayJun 17, 2024 10:36 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc.(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The agreements are for the purchase and sale of 366,000 shares of common stock, or common stock equivalents in lieu thereof, as part of registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement. The shares will be offered at a combined purchase price of $3.75 per share. According to the announcement, the warrants…

Continue Reading

FridayJun 14, 2024 1:20 pm

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Subsidiary Partners with Multistate Testing Lab to Market Proprietary AgLAB Solutions

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its subsidiary, AgLAB, have entered into a master lease agreement with SC Labs; the companies are working together to jointly market the AgLAB 1000-D2(TM) mass spectrometer and the AgLAB Maximum Value Process testing method to SC Labs customers. AgLAB has pioneered applications featuring the Astrotech Mass Spectrometer Technology that specifically target the hemp and cannabis markets while SC Labs, one of the largest multistate cannabis and hemp-testing labs in the United States, delivers industry-leading, science-based innovations in cannabis and hemp testing. The partnership between the two entities extends SC Labs’ analytical services directly…

Continue Reading

ThursdayJun 13, 2024 2:05 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, has received a nonbinding letter of intent (“LOI”) from the European Investment Bank (“EIB”). According to the announcement, the LOI contains terms for converting EIB's loan of approximately $27.6 million into equity in the form of prefunded warrants; the warrants, which will be exercisable into American Depositary Shares (“ADSs”), represent 19.5% of the fully diluted capital of the company as well as capped variable return mostly in the form of…

Continue Reading

TuesdayJun 11, 2024 2:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal EmergingGrowth.com. Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Clene’s President and CEO Rob Etherington and CFO Morgan Brown will provide a keynote speech at the conference starting at 2:20 p.m. ET on June 12. To view the full press release, visit https://ibn.fm/a13Kr About Clene Inc. Clene (along with its…

Continue Reading

TuesdayJun 11, 2024 1:37 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting the results of its recent phase 2/3 Alzheimer’s study. The study was designed to evaluate Buntanetap, the company’s lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans…

Continue Reading

TuesdayJun 11, 2024 1:15 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, will be featured in this week’s Emerging Growth Conference. The conference is slated for June 12–13, 2024. According to the announcement, InMed Pharmaceuticals CEO Eric A. Adams will be presenting at the two-day event. During his presentation, Adams will provide a corporate overview of the company; the presentation will also include a Q&A session. Adams’ presentation is scheduled to begin at 1:45 p.m. EDT on June 13. An archived replay of the presentation will be available on the InMed Pharmaceuticals website.…

Continue Reading

FridayJun 07, 2024 1:49 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company announced today that on June 5, 2024, it received a formal notification from the Listing Qualification Department of the Nasdaq Stock Market that it has regained compliance with the minimum $1.00 bid price requirement outlined in Nasdaq Listing Rule 5550(a)(2). The notification further stated that Scinai remains non-compliant with the equity requirement in Listing Rule 5550(b)(1) or any of the alternative requirements under Listing Rule 5550(b). Accordingly, on June 18, 2024,…

Continue Reading

WednesdayJun 05, 2024 3:58 pm

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures ~$2.2M in Private Placement

Bluejay (NASDAQ: BJDX) is a medical diagnostics company that offers the Symphony technology platform, Symphony Cartridge and tests and testing devices for the diagnosis of allergic conjunctivitis and monitoring of disease progression in critical care settings. Aegis Capital Corp. announced that it acted as exclusive placement agent on a ~$2.2 million private placement for Bluejay Diagnostics. To view the Form 8-K filing, visit https://ibn.fm/3xAyc About Bluejay Diagnostics Inc. Bluejay operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force;…

Continue Reading

WednesdayJun 05, 2024 3:49 pm

BioMedNewsBreaks — Astiva Health Inc. to Host Summer Gala

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, today announced the Astiva Health Summer Gala, to be held at its headquarters in Orange, California. The event marks a significant milestone for the company and is slated to take place from 5 p.m. to 10 p.m. PT on June 29, 2024. The gala will feature live music, a dynamic atmosphere, as well as an important announcement concerning the company’s future plans. A keynote address by Astiva Health’s executive team will highlight strategic initiatives as the company continues its journey towards excellence…

Continue Reading

WednesdayJun 05, 2024 2:34 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced that management will present at the Emerging Growth Conference. Clene’s presentation is slated to begin at 2:20 p.m. on June 12, 2024, and include a corporate presentation with questions and-answers. Interested parties can visit https://ibn.fm/A217J to register for and view the webcast, which will also be available on the Events section of the Clene website. A replay of the presentation will be available as detailed…

Continue Reading